Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

I maintain my buy rating on HQL due to its attractive 14% yield, discounted valuation, and long-term healthcare growth ...

Vantage Wealth bulked up its portfolio by increasing its stake in Amgen by 4.2%, now holding over $21.6 million in shares.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their ...